DE60327811D1 - Sulfhydantoine als phosphatisostere zur verwendung als phosphatasehemmer bei der behandlung von krebs und autoimmunerkrankungen - Google Patents
Sulfhydantoine als phosphatisostere zur verwendung als phosphatasehemmer bei der behandlung von krebs und autoimmunerkrankungenInfo
- Publication number
- DE60327811D1 DE60327811D1 DE60327811T DE60327811T DE60327811D1 DE 60327811 D1 DE60327811 D1 DE 60327811D1 DE 60327811 T DE60327811 T DE 60327811T DE 60327811 T DE60327811 T DE 60327811T DE 60327811 D1 DE60327811 D1 DE 60327811D1
- Authority
- DE
- Germany
- Prior art keywords
- compounds
- treatment
- sulfhydantoines
- phosphatisosteres
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 title abstract 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 title abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 239000000203 mixture Substances 0.000 abstract 2
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 abstract 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 abstract 1
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 abstract 1
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43757202P | 2002-12-30 | 2002-12-30 | |
PCT/US2003/041630 WO2004062664A1 (en) | 2002-12-30 | 2003-12-30 | Sulfhydantoins as phosphate isosteres for use as phosphatase inhibitors in the treatment of cancer and autoimmune disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60327811D1 true DE60327811D1 (de) | 2009-07-09 |
Family
ID=32713206
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60327811T Expired - Lifetime DE60327811D1 (de) | 2002-12-30 | 2003-12-30 | Sulfhydantoine als phosphatisostere zur verwendung als phosphatasehemmer bei der behandlung von krebs und autoimmunerkrankungen |
Country Status (8)
Country | Link |
---|---|
US (1) | US7432292B2 (de) |
EP (1) | EP1594497B1 (de) |
JP (1) | JP4611751B2 (de) |
AT (1) | ATE432074T1 (de) |
AU (2) | AU2003300447B2 (de) |
CA (1) | CA2511818A1 (de) |
DE (1) | DE60327811D1 (de) |
WO (1) | WO2004062664A1 (de) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003032916A2 (en) * | 2001-10-16 | 2003-04-24 | Structural Bioinformatics Inc. | Organosulfur inhibitors of tyrosine phosphatases |
EP1594847A2 (de) * | 2003-02-12 | 2005-11-16 | Transtech Pharma, Inc. | Substituierte azolderivate zur therapeutischen verwendung |
WO2005035551A2 (en) | 2003-10-08 | 2005-04-21 | Incyte Corporation | Inhibitors of proteins that bind phosphorylated molecules |
CA2551909C (en) * | 2004-02-12 | 2011-10-11 | Transtech Pharma, Inc. | Substituted azole derivatives, compositions, and methods of use |
US20060135773A1 (en) * | 2004-06-17 | 2006-06-22 | Semple Joseph E | Trisubstituted nitrogen modulators of tyrosine phosphatases |
EP1786421A2 (de) * | 2004-07-09 | 2007-05-23 | Cengent Therapeutics, Inc. | Sauerstoff/stickstoff-heterozyklus-hemmer von tyrosinphosphatasen |
WO2006028970A1 (en) | 2004-09-02 | 2006-03-16 | Cengent Therapeutics, Inc. | Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases |
EP1728790A1 (de) | 2005-06-01 | 2006-12-06 | Max-Delbrück-Centrum Für Molekulare Medizin | Shp-2-Inhibitoren, Arzneimittel, die sie enthalten sowie deren Verwendung zur Behandlung von Phosphatasen-vermittelten Krankheiten |
AU2006321904A1 (en) * | 2005-12-08 | 2007-06-14 | Novartis Ag | 1, 1, 3-trioxo-1 , 2 , 5-thiadiazolidines and their use as PTP-ases inhibitors |
CA2629819A1 (en) * | 2005-12-08 | 2007-06-14 | Novartis Ag | 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (ptpase) |
UA94724C2 (en) * | 2005-12-08 | 2011-06-10 | Новартис Аг | Thiadiazolidinone derivatives as antidiabetic agents |
UA94921C2 (en) * | 2005-12-08 | 2011-06-25 | Новартис Аг | 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors |
EP1991544B1 (de) | 2006-01-30 | 2018-08-15 | vTv Therapeutics LLC | Substituierte imidazol- derivate und ihre verwendung als ptpase inhibitoren |
AU2007233251A1 (en) * | 2006-03-31 | 2007-10-11 | Novartis Ag | Thiadiazolidinone inhibitors of PTPase |
WO2010011666A2 (en) * | 2008-07-21 | 2010-01-28 | University Of South Florida | Indoline scaffold shp-2 inhibitors and cancer treatment method |
EP2552451A1 (de) * | 2010-03-29 | 2013-02-06 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Proteintyrosinphosphatase, nicht-rezeptor typ 11 (ptpn11) und tumorinitiierende zellen |
WO2012041524A1 (en) | 2010-10-01 | 2012-04-05 | Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) | Hydrazonopyrazolones as protein tyrosine phosphatase inhibitors |
WO2012168259A1 (en) * | 2011-06-06 | 2012-12-13 | Novartis Forschungsstiftung, Zweigniederlassung | Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer |
CN103087166B (zh) * | 2011-10-31 | 2014-03-05 | 中国科学院微生物研究所 | 一种钾氢泵蛋白及其编码基因和它们的应用 |
CA2953482A1 (en) | 2013-07-03 | 2015-01-08 | Indiana University Research & Technology Corporation | Shp2 inhibitors and methods of treating autoimmune and/or glomerulonephritis-associated diseases using shp2 inhibitors |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US555609A (en) * | 1896-03-03 | Yarn-dyeing machine | ||
US4952397A (en) * | 1985-06-17 | 1990-08-28 | Merck & Co., Inc. | 2-quaternary heteroarylalkylthio carbapenems having an acid moiety substituent |
US5550139A (en) * | 1994-01-03 | 1996-08-27 | The Wichita State University | Serine protease inhibitors |
US5541168A (en) | 1994-12-02 | 1996-07-30 | Sterling Winthrop Inc. | Substituted 2-(phosphinyloxymethyl)-1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof |
US5494925A (en) * | 1994-12-02 | 1996-02-27 | Sterling Winthrop Inc. | 2-heterocyclyloxymethyl and 2-heterocyclylthiomethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof |
US5512576A (en) * | 1994-12-02 | 1996-04-30 | Sterling Winthrop Inc. | 2-substituted 1,2,5,-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof |
US5556909A (en) | 1994-12-02 | 1996-09-17 | Sanofi Winthrop Inc. | Substituted 2-arylcarbonyloxymethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxide derivatives and compositions and method of use thereof |
US5750546A (en) | 1994-12-02 | 1998-05-12 | Sanofi Winthrop, Inc. | 2-(2, 3, 5, 6-tetrafluoro-4-pyridyl)-1, 2, 5-thiadiazolidin-3-one 1, 1-dioxides and compositions and method of use thereof |
EP1492780B1 (de) * | 2002-04-03 | 2011-11-23 | Novartis AG | 5-substituierte 1,1-dioxo-¬1,2,5 thiazolidin-3-onderivate als ptpase 1b hemmer |
GB0227813D0 (en) * | 2002-11-29 | 2003-01-08 | Astrazeneca Ab | Chemical compounds |
-
2003
- 2003-12-30 AT AT03815258T patent/ATE432074T1/de not_active IP Right Cessation
- 2003-12-30 JP JP2004566641A patent/JP4611751B2/ja not_active Expired - Fee Related
- 2003-12-30 EP EP03815258A patent/EP1594497B1/de not_active Expired - Lifetime
- 2003-12-30 CA CA002511818A patent/CA2511818A1/en not_active Abandoned
- 2003-12-30 AU AU2003300447A patent/AU2003300447B2/en not_active Ceased
- 2003-12-30 WO PCT/US2003/041630 patent/WO2004062664A1/en active Application Filing
- 2003-12-30 US US10/749,121 patent/US7432292B2/en not_active Expired - Fee Related
- 2003-12-30 DE DE60327811T patent/DE60327811D1/de not_active Expired - Lifetime
-
2009
- 2009-12-03 AU AU2009243502A patent/AU2009243502A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2009243502A1 (en) | 2009-12-24 |
AU2003300447A1 (en) | 2004-08-10 |
CA2511818A1 (en) | 2004-07-29 |
WO2004062664A1 (en) | 2004-07-29 |
EP1594497B1 (de) | 2009-05-27 |
US20040167187A1 (en) | 2004-08-26 |
AU2003300447B2 (en) | 2009-09-03 |
JP4611751B2 (ja) | 2011-01-12 |
EP1594497A1 (de) | 2005-11-16 |
ATE432074T1 (de) | 2009-06-15 |
JP2006514960A (ja) | 2006-05-18 |
US7432292B2 (en) | 2008-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE432074T1 (de) | Sulfhydantoine als phosphatisostere zur verwendung als phosphatasehemmer bei der behandlung von krebs und autoimmunerkrankungen | |
ATE443043T1 (de) | Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer | |
ATE527261T1 (de) | 7-aryl-3,9-diazabicycloä3.3.1ünon-6-en-derivate und ihre verwendung als renin-inhibitoren zur behandlung von bluthochdruck, herz-kreislauf- erkrankungen und nierenkrankheiten | |
ATE232873T1 (de) | Phosphonsaürederivate als ptp-1b-inhibitoren | |
IS6852A (is) | Efnasambönd | |
AP1744A (en) | Inhibitors of factor XA and other serine proteases involved in the coagulation cascade | |
ID18143A (id) | Penghambat metaloprotease amina siklik tersubstitusi | |
ATE253545T1 (de) | Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren | |
UA93882C2 (ru) | Пиперидинил-замещенные производные изохинолона kak ингибиторы rho-киназы | |
BR0309281A (pt) | Triaril-oxi-espiro-pirimidino-2,4,6-trionas inibidoras de metaloproteinases | |
TNSN08038A1 (en) | Cyclohexylamin isoquinolone derivatives as rho-kinase inhibitors | |
ATE433447T1 (de) | Pyrimiidinverbindungen | |
NO20040945L (no) | Benzotiepin ileal gallesyre transport inhibitorer | |
ATE383160T1 (de) | Phosphinsäurederivate, inhibitoren von beta- sekretase zur behandlung von alzheimer-krankheit | |
UY27431A1 (es) | Compuestos químicos | |
FI956119A0 (fi) | Fenyyliheterosyklejä syklo-oksigenaasi-2-inhibiittoreina | |
ATE374200T1 (de) | 7-azaindole als inhibitoren c-jun n-terminaler kinasen zur behandlung neurodegenerativer störungen | |
BR0316350A (pt) | Diaminotriazóis úteis como inibidores de proteìna cinases | |
ATE524181T1 (de) | Verwendung von 1,4-bis (3-aminoalkyl) piperazin- derivaten bei der behandlung von neurodegenerativen erkrankungen | |
DE602004019548D1 (de) | Kondensierte heterocyclen als inhibitoren von glutamatracemase (muri) | |
ATE538651T1 (de) | Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
PT1163208E (pt) | Inibidores de caspase e as suas utilizacoes | |
EP1689713A4 (de) | Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
ATE432278T1 (de) | Verbindungen zur behandlung von krankheiten | |
ATE512147T1 (de) | Makrozyklische aminiopyridyl-beta-sekretase- hemmer zur behandlung von morbus alzheimer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |